New Brunswick Family Medicine · 200 patients
Good evening, Dr. Rivera.
24 trials fit your patients, with 399 pre-screen candidates between them. Ranked by how many of your patients could join. We pre-screened your panel against 39 open trials on Oct 11, 2026; patient records never left your practice.
Ebola Virus Disease
Ervebo
Ebola virus disease (EVD) is emerging regularly in various African countries for various reasons: during contact with mortal remains, during an unsafe burial or following the viral dissemination around a recovered patient. However, tools to fight the spread of the disease are being made available to countries affected…
- Ages
- 18+
- Sex
- All
- Enrolling
- 132
- Ends
- Aug 2027
Overweight or Obesity
REGN20934
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times *…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 90
- Ends
- Feb 2027
Overweight or Obesity
Olatorepatide
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by…
- Ages
- 18+
- Sex
- All
- Enrolling
- 360
- Ends
- Jan 2028
Healthy Volunteer
REGN22044
This clinical study will evaluate the study drug, REGN22044, in healthy participants. REGN22044 has not previously been studied in humans. The purpose of this study is to learn: * What side effects may happen when REGN22044 is taken * How much of REGN22044 is in the blood at different times * Whether the body makes…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 88
- Ends
- Feb 2027
Hypercholesterolemia
Alirocumab
This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels). The aim of the study is to see how safe and effective alirocumab is when given weekly to adult…
- Ages
- 18–80
- Sex
- All
- Enrolling
- 420
- Ends
- Dec 2026
Diabetic Kidney Disease
Evinacumab
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side…
- Ages
- 18–80
- Sex
- All
- Enrolling
- 195
- Ends
- Oct 2028
Advanced Solid Tumors
REGN13089-M404-M2980
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body). The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial…
- Ages
- 18+
- Sex
- All
- Enrolling
- 320
- Ends
- Mar 2031
Atopic Dermatitis
Dupixent
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
- Ages
- 18+
- Sex
- All
- Enrolling
- 40
- Ends
- Dec 2024
Healthy Volunteer
REGN20423
This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 144
- Ends
- Jun 2028
Atrial Fibrillation
REGN7508
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in…
- Ages
- 18+
- Sex
- All
- Enrolling
- 2,628
- Ends
- Mar 2029
Atrial Fibrillation
REGN7508
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the…
- Ages
- 18+
- Sex
- All
- Enrolling
- 1,200
- Ends
- Feb 2027
Alzheimer's Disease
ALN-5288
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
- Ages
- 40–80
- Sex
- All
- Enrolling
- 50
- Ends
- Mar 2030
Symptomatic Venous Thromboembolism
REGN7508
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective…
- Ages
- 18+
- Sex
- All
- Enrolling
- 2,000
- Ends
- May 2027
Venous Thromboembolism
REGN7508
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related…
- Ages
- 18+
- Sex
- All
- Enrolling
- 2,000
- Ends
- Feb 2027
Asthma Control
Dupilumab Prefilled Syringe
This study tests whether an asthma medication called dupilumab can help people achieve complete asthma control (called "remission") when given earlier in their disease, before asthma becomes severe. Currently, most people with asthma only receive advanced treatments like biologics after their condition has worsened…
- Ages
- 18–79
- Sex
- All
- Enrolling
- 150
- Ends
- Jan 2029
Advanced Solid Tumor
89Zr˗DFO˗REGN5054
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer. The aim of the study is…
- Ages
- 18+
- Sex
- All
- Enrolling
- 50
- Ends
- May 2027
Cancer-Associated Thrombosis
REGN7508
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are…
- Ages
- 18+
- Sex
- All
- Enrolling
- 1,120
- Ends
- Jan 2030
Familial Hypercholesterolemia
Supportive care
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the…
- Ages
- 18–120
- Sex
- All
- Enrolling
- 250
- Ends
- May 2027
Atrial Fibrillation
REGN7508
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how safe and effective…
- Ages
- 18+
- Sex
- All
- Enrolling
- 15,364
- Ends
- Sep 2029
Colo-rectal Cancer
Cemiplimab
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different…
- Ages
- 18+
- Sex
- All
- Enrolling
- 79
- Ends
- Apr 2029
Metastatic Castration-Resistant Prostate Cancer
REGN5678
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of…
- Ages
- 18+
- Sex
- All
- Enrolling
- 345
- Ends
- Nov 2027
Atopic Dermatitis
Dupilumab
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Dec 2026
Melanoma
REGN10597
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study…
- Ages
- 18+
- Sex
- All
- Enrolling
- 240
- Ends
- Feb 2030
Venous Thromboembolism
REGN7508
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part 1) or focused on…
- Ages
- 18+
- Sex
- All
- Enrolling
- 1,600
- Ends
- Jul 2031
No candidates in your panel· 123
Open trials where none of your patients pre-screened as a candidate or for chart review, or that haven't been pre-screened yet.
Advanced Melanoma
Fianlimab
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
- Ages
- 18+
- Sex
- All
- Enrolling
- 88
- Ends
- Sep 2027
Age-related Macular Degeneration
Pozelimab
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting…
- Ages
- 50–85
- Sex
- All
- Enrolling
- 975
- Ends
- Jul 2028
Head and Neck Cancer
Cetuximab
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to…
- Ages
- 18+
- Sex
- All
- Enrolling
- 40
- Ends
- Jun 2027
Melanoma
Fianlimab
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and…
- Ages
- 18+
- Sex
- All
- Enrolling
- 560
- Ends
- Mar 2027
Recurrent Lung Non-Small Cell Carcinoma
Cemiplimab
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a…
- Ages
- 18+
- Sex
- All
- Enrolling
- 378
- Ends
- Dec 2027
Prostate Cancer
BPX-601
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of…
- Ages
- 18+
- Sex
- Male
- Enrolling
- 36
- Ends
- Feb 2030
Diffuse Large B-cell Lymphoma
Odronextamab
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come…
- Ages
- 18+
- Sex
- All
- Enrolling
- 904
- Ends
- Mar 2028
Epithelial Ovarian Cancer
Cemiplimab
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2)…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 90
- Ends
- May 2030
Metastatic Castration-resistant Prostate Cancer
REGN4336
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (how the body reacts…
- Ages
- 18+
- Sex
- Male
- Enrolling
- 228
- Ends
- Mar 2030
B-cell Non-Hodgkins Lymphoma
Odronextamab
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose…
- Ages
- 18+
- Sex
- All
- Enrolling
- 107
- Ends
- Feb 2029
Multiple Myeloma
Linvoseltamab
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell…
- Ages
- 18+
- Sex
- All
- Enrolling
- 149
- Ends
- Nov 2035
Non-Small Cell Lung Cancer
Cemiplimab
ARCH is a randomised, stratified, multicentre, phase III trial. Protocol treatment consists of cemiplimab, 350 mg i.v., every 3 weeks, for 4 cycles, followed by 700 mg i.v., every 6 weeks for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first. The primary objective of the study is to…
- Ages
- 18+
- Sex
- All
- Enrolling
- 390
- Ends
- Mar 2029
Paroxysmal Nocturnal Hemoglobinuria
ALN-CFB
This study is researching an experimental drug called ALN-CFB. The study is focused on people with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are currently taking a complement component C5 inhibitor ("C5-inhibitor") and continue to have anemia (low red blood cell count). The aim of the study is to see how tolerable…
- Ages
- 18+
- Sex
- All
- Enrolling
- 24
- Ends
- Nov 2029
B-cell Non Hodgkin Lymphoma
Odronextamab
The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the…
- Ages
- Up to 25
- Sex
- All
- Enrolling
- 210
- Ends
- May 2031
Prostate Cancer
REGN5678
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
- Ages
- 18+
- Sex
- Male
- Enrolling
- 60
- Ends
- May 2027
Metabolic Dysfunction-Associated Steatotic Liver Disease
Tirzepatide
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 204
- Ends
- Mar 2030
Neuromuscular Disease
Nexiguran ziclumeran
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
- Ages
- 18–85
- Sex
- All
- Enrolling
- 60
- Ends
- Jul 2027
Metabolic Dysfunction-Associated SteatoHepatitis
ALN-HSD
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 120
- Ends
- Apr 2028
Monoclonal Gammopathy of Undetermined Significance
Linvoseltamab
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance…
- Ages
- 18+
- Sex
- All
- Enrolling
- 116
- Ends
- May 2032
Advanced Renal Cell Carcinoma
Fianlimab
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
- Ages
- 18+
- Sex
- All
- Enrolling
- 120
- Ends
- Nov 2029
Juvenile Idiopathic Arthritis
Sarilumab SAR153191 (REGN88)
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the…
- Ages
- 1–17
- Sex
- All
- Enrolling
- 51
- Ends
- Mar 2028
High-Grade Glioma
Cemiplimab
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs"). The study is focused on children and young adults with recurrent or progressive High-Grade Glioma (HGG) or ependymoma. "Recurrent" means…
- Ages
- 0–39
- Sex
- All
- Enrolling
- 120
- Ends
- Aug 2032
Locally Advanced Basal Cell Carcinoma
Cemiplimab
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC. The study is looking at: * What side effects cemiplimab, alone or in a combination treatment, might cause * How…
- Ages
- 18+
- Sex
- All
- Enrolling
- 135
- Ends
- Nov 2030
Monogenic Obesity
Mibavademab
This study is researching an experimental drug called mibavademab. The study is focused on patients with a condition called monogenic obesity. Monogenic obesity is caused by a change in the leptin gene that keeps it from working properly. This causes the body to not be able to feel full or control feelings of hunger.…
- Ages
- 2+
- Sex
- All
- Enrolling
- 4
- Ends
- Jun 2027
Paroxysmal Nocturnal Hemoglobinuria
Pozelimab
This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with…
- Ages
- 18+
- Sex
- All
- Enrolling
- 202
- Ends
- Oct 2028
Nasopharyngeal Carcinoma
Cemiplimab
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
- Ages
- 18+
- Sex
- All
- Enrolling
- 60
- Ends
- Jul 2030
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene
DB-OTO
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety…
- Ages
- Any age
- Sex
- All
- Enrolling
- 36
- Ends
- Feb 2029
Eosinophilic Esophagitis
Dupilumab
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study…
- Ages
- 0.5–6
- Sex
- All
- Enrolling
- 20
- Ends
- Jun 2028
Relapsed/Refractory Multiple Myeloma
Linvoseltamab
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined). This study is the first time REGN7945 will be tested in humans. Linvoseltamab has…
- Ages
- 18+
- Sex
- All
- Enrolling
- 186
- Ends
- Nov 2033
High Risk Smoldering Multiple Myeloma
Linvoseltamab
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developing active multiple myeloma. The aim of this study is to find out whether…
- Ages
- 18+
- Sex
- All
- Enrolling
- 270
- Ends
- Jul 2033
Relapsed and/or Refractory Multiple Myeloma
Linvoseltamab
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this…
- Ages
- 18+
- Sex
- All
- Enrolling
- 915
- Ends
- May 2029
Metabolic Dysfunction-Associated Steatotic Liver Disease
ALN-CIDEB
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 132
- Ends
- May 2027
Paroxysmal Nocturnal Hemoglobinuria
Pozelimab
This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as "study drugs". Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works…
- Ages
- 18+
- Sex
- All
- Enrolling
- 35
- Ends
- Jan 2030
Allergic Conjunctivitis
REGN-2Cat
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs". The aim of the study is to see what side effects…
- Ages
- 8+
- Sex
- All
- Enrolling
- 570
- Ends
- May 2029
Multiple Myeloma
Linvoseltamab
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior…
- Ages
- 18+
- Sex
- All
- Enrolling
- 317
- Ends
- Mar 2028
Ovarian Cancer
REGN5668
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 612
- Ends
- Nov 2028
Chronic Obstructive Pulmonary Disease
Dupilumab
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with…
- Ages
- 40–85
- Sex
- All
- Enrolling
- 218
- Ends
- Dec 2028
Functional Hypothalamic Amenorrhea
Mibavademab
This study is researching an experimental drug called mibavademab (also called "study drug"). The study is focused on participants with a condition called Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the…
- Ages
- 18–40
- Sex
- Female
- Enrolling
- 34
- Ends
- Jan 2028
Prurigo Nodularis
Dupilumab
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including…
- Ages
- 0.5–17
- Sex
- All
- Enrolling
- 18
- Ends
- Oct 2027
Hemophilia B
REGV131
Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study…
- Ages
- 2+
- Sex
- Male
- Enrolling
- 130
- Ends
- Aug 2034
Fibrodysplasia Ossificans Progressiva
Garetosmab
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP. For United States: Ages 4 to less than 18 years; for non-US sites only: Ages 2 to less than 18 years. The aim of the study is to see how safe, tolerable,…
- Ages
- 2–18
- Sex
- All
- Enrolling
- 18
- Ends
- Jul 2030
Non Small Cell Lung Cancer
Ubamatamab
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and…
- Ages
- 18+
- Sex
- All
- Enrolling
- 300
- Ends
- Jun 2030
Multiple Myeloma
Linvoseltamab
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab…
- Ages
- 18+
- Sex
- All
- Enrolling
- 1,000
- Ends
- Dec 2036
Head and Neck Squamous Cell Carcinoma
FDC fianlimab+cemiplimab
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is…
- Ages
- 18+
- Sex
- All
- Enrolling
- 120
- Ends
- Jun 2028
CHAPLE Disease
Pozelimab
This study is researching a drug called pozelimab (called "study drug"). The main aim of this study is to monitor the safety and tolerability of the study drug. The study is focused on young children 1 to 5 years of age, who have CHAPLE disease. CHAPLE is a very rare hereditary disease that can cause potentially…
- Ages
- 1–5
- Sex
- All
- Enrolling
- 5
- Ends
- Feb 2030
Prion Disease
ALN-6457
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD). In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement. ALN-6457…
- Ages
- 18+
- Sex
- All
- Enrolling
- 60
- Ends
- Feb 2031
Relapsed/Refractory Follicular Lymphoma
Odronextamab
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or…
- Ages
- 18+
- Sex
- All
- Enrolling
- 580
- Ends
- Apr 2031
Relapsed Refractory Multiple Myeloma
Linvoseltamab
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These…
- Ages
- 18+
- Sex
- All
- Enrolling
- 410
- Ends
- Apr 2033
Healthy Volunteers
ALN-PNP
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment. This study consists of 3 parts. Part A is focused on…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 172
- Ends
- Aug 2027
Relapsed/Refractory Systemic Light Chain Amyloidosis
Linvoseltamab
This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): * In Phase 1, linvoseltamab will be given to…
- Ages
- 18+
- Sex
- All
- Enrolling
- 220
- Ends
- Aug 2028
Follicular Lymphoma
Odronextamab
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized -…
- Ages
- 18+
- Sex
- All
- Enrolling
- 822
- Ends
- Feb 2028
Relapsed Refractory Multiple Myeloma
Linvoseltamab
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the…
- Ages
- 18+
- Sex
- All
- Enrolling
- 150
- Ends
- Sep 2033
Nsclc
Cemiplimab
This research study is being done to find out if a drug called cemiplimab is safe in adult patients who have non-small cell lung cancer (NSCLC) that can be surgically removed (resectable Stage II, IIIA, or select IIIB NSCLC). The purpose of this study is also to look at how well the study drug works and whether…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Sep 2030
Relapsed/Refractory Multiple Myeloma
Linvoseltamab
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who have already been treated with at least four lines of treatment for their multiple…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Oct 2027
Hemodialysis
Alirocumab 150 MG/ML [Praluent]
12-week study of the efficacy and safety of alirocumab in patients maintained stably on hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9 levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at weeks 4, 8, 10 and 12 weeks. Safety events will…
- Ages
- 18–80
- Sex
- All
- Enrolling
- 20
- Ends
- Aug 2020
Colorectal Cancer
Cemiplimab
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-positive, T3…
- Ages
- 18+
- Sex
- All
- Enrolling
- 66
- Ends
- Jul 2030
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Cemiplimab
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
- Ages
- 18+
- Sex
- All
- Enrolling
- 17
- Ends
- May 2027
Kidney Transplant Recipient
Cemiplimab
This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemiplimab alongside standardized immune…
- Ages
- 18+
- Sex
- All
- Enrolling
- 22
- Ends
- Mar 2031
Clear Cell Renal Cell Carcinoma
Cemiplimab 350 MG Intravenous Solution
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.
- Ages
- 18+
- Sex
- All
- Enrolling
- 72
- Ends
- Aug 2029
Pancreatic Ductal Adenocarcinoma
Cemiplimab Plus Gemcitabine
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIRINOX…
- Ages
- 18+
- Sex
- All
- Enrolling
- 43
- Ends
- Jul 2028
Cutaneous Basal Cell Carcinoma
Cemiplimab
Basal cutaneous cell carcinoma (BCC) is the most common skin cancer. Early-stage disease is managed with surgery or radiation that cure more than 95% of patients. Surgical excision is the treatment of choice and by far the most convenient and effective means of achieving cure of any invasive BCC, Surgery is rarely…
- Ages
- 18+
- Sex
- All
- Enrolling
- 18
- Ends
- Dec 2028
Colon Cancer
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
This is a research study to test whether two immunotherapy drugs-cemiplimab and fianlimab-can safely and effectively shrink colon tumors before surgery in people with stage II-III colon cancer that has not spread to other parts of the body. Participants will receive two doses of the study drugs through an IV (one on…
- Ages
- 18+
- Sex
- All
- Enrolling
- 24
- Ends
- Dec 2028
Colorectal Cancer
Cemiplimab
The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery…
- Ages
- 18+
- Sex
- All
- Enrolling
- 44
- Ends
- May 2030
Multiple Myeloma
Isatuximab
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 720
- Ends
- Oct 2033
Lupus Nephritis
Odronextamab
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study,…
- Ages
- 18–60
- Sex
- All
- Enrolling
- 90
- Ends
- Sep 2029
Pruritis
Dupilumab
The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
- Ages
- 18–60
- Sex
- All
- Enrolling
- 46
- Ends
- Jan 2026
Eosinophilic Esophagitis
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE…
- Ages
- 22+
- Sex
- All
- Enrolling
- 30
- Ends
- Sep 2026
Generalized Lipodystrophy
Mibavademab
This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the…
- Ages
- 2+
- Sex
- All
- Enrolling
- 28
- Ends
- May 2028
Hidradenitis Suppurativa
Olatorepatide
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and…
- Ages
- 18+
- Sex
- All
- Enrolling
- 300
- Ends
- Nov 2028
Sporadic Inclusion Body Myositis
Pozelimab/Cemdisiran
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
- Ages
- 45–75
- Sex
- All
- Enrolling
- 10
- Ends
- May 2027
Melanoma BRAF V600E/K Mutated
Cemiplimab+fianlimab
Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is urgent that the investigators identify…
- Ages
- 18+
- Sex
- All
- Enrolling
- 33
- Ends
- Jan 2028
Basal Cell Carcinoma
Cemiplimab
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
- Ages
- 18+
- Sex
- All
- Enrolling
- 34
- Ends
- Oct 2028
Amyotrophic Lateral Sclerosis
ALN-SOD
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be…
- Ages
- 18+
- Sex
- All
- Enrolling
- 54
- Ends
- Mar 2032
Parkinsons Disease
ALN-SNCA
This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, especially those due to the harmful…
- Ages
- 50–80
- Sex
- All
- Enrolling
- 46
- Ends
- Jun 2029
Colon and Rectal Cancer
Cemiplimab
This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
- Ages
- 18+
- Sex
- All
- Enrolling
- 20
- Ends
- Jan 2028
Bladder Cancer
Cemiplimab
The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults. The main question it aims to answer is: Can gemcitabine, cisplatin, and cemiplimab with or without fianlimab treat bladder cancer? Participants will be randomly…
- Ages
- 18+
- Sex
- All
- Enrolling
- 36
- Ends
- Dec 2028
Diabetic Macular Edema
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues. Patients may have improved DME with anti-VEGF therapy and ranibizumab has been found to reduce central macular thickness (CMT) with anti-VEGF therapy following vitrectomy. Those…
- Ages
- 21+
- Sex
- All
- Enrolling
- 15
- Ends
- Aug 2026
Multiple Myeloma
Linvoseltamab
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out…
- Ages
- 18+
- Sex
- All
- Enrolling
- 150
- Ends
- Aug 2027
Nasal Polyps
Dupilumab Prefilled Syringe
Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity. Primary Objective will be to demonstrate that dupilumab…
- Ages
- 18–65
- Sex
- All
- Enrolling
- 20
- Ends
- Jun 2026
Geographic Atrophy
Pozelimab
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and…
- Ages
- 50+
- Sex
- All
- Enrolling
- 54
- Ends
- Jul 2028
Ovarian Cancer
Ubamatamab
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 297
- Ends
- Jun 2028
Glioblastoma
Cemiplimab
This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled…
- Ages
- 18+
- Sex
- All
- Enrolling
- 99
- Ends
- Feb 2031
Multiple Myeloma
Linvoseltamab
The purpose of this study is to determine whether giving linvoseltamab with lenalidomide during maintenance treatment to participants with multiple myeloma will: 1. Get rid of any residual multiple myeloma cells in participants' bodies which is known as minimal residual disease negative (MRD-) status. For participants…
- Ages
- Any age
- Sex
- All
- Enrolling
- 32
- Ends
- Dec 2032
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
NTLA-2001
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
- Ages
- 18–90
- Sex
- All
- Enrolling
- 1,200
- Ends
- Dec 2027
Merkel Cell Carcinoma
Cemiplimab-Rwlc
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
- Ages
- 18+
- Sex
- All
- Enrolling
- 36
- Ends
- Mar 2028
Non-small Cell Lung Cancer Stage III
Cemiplimab-Rwlc
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node involvement or other high-risk subsets in which there is no consensus on resectability. The…
- Ages
- 18+
- Sex
- All
- Enrolling
- 21
- Ends
- Dec 2027
Merkel Cell Carcinoma, Stage I
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph…
- Ages
- 18+
- Sex
- All
- Enrolling
- 135
- Ends
- Dec 2029
Recurrent Diffuse Large B-Cell Lymphoma
Odronextamab
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab…
- Ages
- 18+
- Sex
- All
- Enrolling
- 27
- Ends
- Apr 2028
Follicular Lymphoma
Odronextamab
The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab. The name of the study drug in this research study is: -Odronextamab (a type of monoclonal antibody)
- Ages
- 18+
- Sex
- All
- Enrolling
- 35
- Ends
- Jan 2027
NSCLC
Cemiplimab
The goal of IMMUNOLIFE2 is to overcome primary resistance to immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab used alone or in combination with chemotherapy, observed in patients with advanced non-small cell lung cancer (NSCLC) following antibiotic exposure, which induces intestinal dysbiosis.…
- Ages
- 18+
- Sex
- All
- Enrolling
- 162
- Ends
- Sep 2030
Lung Cancer
Cemiplimab
This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the…
- Ages
- 18+
- Sex
- All
- Enrolling
- 33
- Ends
- Dec 2027
Multiple Myeloma
Linvoseltamab
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: *…
- Ages
- 18+
- Sex
- All
- Enrolling
- 387
- Ends
- Mar 2033
Rheumatoid Arthritis
Sarilumab, SAR153191 SC
This is a Phase 1/Phase 2 study with: * 5-arms design for Part A; * and a single arm for Part B. The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in male and female…
- Ages
- 18+
- Sex
- All
- Enrolling
- 140
- Ends
- Oct 2028
Solid Tumors
Cemiplimab
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.
- Ages
- 18+
- Sex
- All
- Enrolling
- 40
- Ends
- Sep 2028
Acute Myeloid Leukemia
SC-DARIC33
A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product that has been…
- Ages
- Up to 30
- Sex
- All
- Enrolling
- 18
- Ends
- Feb 2028
Carcinoma, Non-Small-Cell Lung
Cemiplimab
The goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC). Before surgery to remove their lung cancer, participants will take: 1. Cemiplimab with…
- Ages
- 18+
- Sex
- All
- Enrolling
- 112
- Ends
- Dec 2026
Non Small Cell Lung Cancer
Cemiplimab 350 mg IV
Traditionally, chemotherapy and/or immunotherapy are combined with surgery or radiotherapy to cure patients with lung cancer. However, some patients treated with immunotherapy appear to be cured before surgery or radiotherapy. In this study, patients with a high chance to respond to immunotherapy will be selected.…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Dec 2029
Peripheral Artery Disease
REGN7508
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures…
- Ages
- 18+
- Sex
- All
- Enrolling
- 7,050
- Ends
- Aug 2029
Alopecia Areata
Dupilumab
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA…
- Ages
- 18+
- Sex
- All
- Enrolling
- 76
- Ends
- Nov 2027
Metastatic Castration-Resistant Prostate Cancer
REGN15505
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use…
- Ages
- 18+
- Sex
- All
- Enrolling
- 265
- Ends
- Oct 2030
Metastatic Castration-Resistant Prostate Cancer
REGN21353
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or mCRPC). Some participants may get additional experimental drugs in combination with…
- Ages
- 18+
- Sex
- Male
- Enrolling
- 192
- Ends
- Jul 2031
Primary Open Angle Glaucoma
REGN22530
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and…
- Ages
- 18+
- Sex
- All
- Enrolling
- 271
- Ends
- Sep 2029
Recurrent Multiple Myeloma
Linvoseltamab
This phase I/II trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myeloma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is resistant to three classes of…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Jun 2028
Ovarian Cancer
Ubamatamab
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab? * What is…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 43
- Ends
- Sep 2028
Clonal Cytopenia of Undetermined Significance
REGN17235
This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation). The study is looking at: * What side effects the study drug might…
- Ages
- 18+
- Sex
- All
- Enrolling
- 52
- Ends
- May 2031
Polymyalgia Rheumatica
Sarilumab
This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in…
- Ages
- 50+
- Sex
- All
- Enrolling
- 300
- Ends
- Jun 2029
End-Stage Kidney Disease
REGN9933
This study will evaluate three Investigational Medicinal Products (IMPs) called REGN9933, REGN7508, and REGN9533. The study is focused on participants with End-Stage Kidney Disease (ESKD) treated with hemodialysis and standard anticoagulant treatment, such as heparin, to reduce the risk of blood clots as they can lead…
- Ages
- 18+
- Sex
- All
- Enrolling
- 36
- Ends
- Apr 2027
Metastatic Uveal Melanoma
ZIV-Aflibercept
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can…
- Ages
- 18+
- Sex
- All
- Enrolling
- 32
- Ends
- Oct 2030
Cutaneous Squamous Cell Carcinoma
Cemiplimab
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune…
- Ages
- 18+
- Sex
- All
- Enrolling
- 369
- Ends
- May 2030
Pulmonary Arterial Hypertension
REGN13335
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other…
- Ages
- 18+
- Sex
- All
- Enrolling
- 99
- Ends
- Feb 2028
Recurrent Ovarian Cancer
Ubamatamab
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 890
- Ends
- May 2027
Any Advanced Solid Tumors
Sarilumab
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm…
- Ages
- 18+
- Sex
- All
- Enrolling
- 41
- Ends
- Aug 2029
Metabolic Dysfunction-Associated Steatohepatitis
ALN-CIDEB
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver injury, and liver scarring. The study will compare ALN-CIDEB with placebo to understand how well…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 150
- Ends
- Feb 2029
Chronic Obstructive Pulmonary Disease
Dupilumab
This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment…
- Ages
- 40+
- Sex
- All
- Enrolling
- 754
- Ends
- Jul 2028
NSCLC
Cemiplimab
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
- Ages
- 18+
- Sex
- All
- Enrolling
- 76
- Ends
- Aug 2027
Graves' Disease
REGN24493
This study will test an experimental Regeneron drug called REGN24493 hereby referred to as "study drug" to see if it can help treat Graves' disease. Graves' disease is a condition where the immune system causes the thyroid gland to make too much thyroid hormone. The main purpose of this study is to learn about the…
- Ages
- 18+
- Sex
- All
- Enrolling
- 45
- Ends
- Jan 2030
Pleural Mesotheliomas
Cemiplimab
This is a multicentre, phase IIR, double non-comparative arm trial, with an initial safety run for the anti-LAG3 arm. Approximately 40 sites will participate in the study and will enroll 126 patients with treatment-naive, unresectable malignant PM. Treatment will be administered in 21-day cycles and will continue…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 126
- Ends
- May 2028
HPV-Related Squamous Cell Carcinoma
Cemiplimab
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus chemotherapy) to reduce treatment intensity and improve long-term quality of life while maintaining very high cure rates.
- Ages
- 18+
- Sex
- All
- Enrolling
- 32
- Ends
- Jun 2027
Metabolic Dysfunction-Associated Steatotic Liver Disease
ALN-CIDEB
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD. MASLD is a liver condition caused by too much fat building up in the liver.…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 1,500
- Ends
- Mar 2029
Atopic Dermatitis
Dupilumab
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
- Ages
- 6–17
- Sex
- All
- Enrolling
- 40
- Ends
- Jun 2027
Venous Thromboembolism
REGN7508
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted Central Catheter \[PICC\]). Patients with PICCs have a higher risk of getting blood clots…
- Ages
- 15+
- Sex
- All
- Enrolling
- 1,908
- Ends
- Jun 2029
Asthma
Dupilumab Injectable Product
Often when people with asthma get a virus caused by the common cold (rhinovirus), they also experience an increase or worsening of their asthma symptoms. The purpose of this study is to see if the study medication dupilumab helps prevent those with mild to moderate asthma from having increased asthma symptoms, after…
- Ages
- 18–40
- Sex
- All
- Enrolling
- 60
- Ends
- Jun 2026
Anaplastic Thyroid Cancer
Cemiplimab
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
- Ages
- 18+
- Sex
- All
- Enrolling
- 12
- Ends
- Mar 2028